Absorb IV Randomized Controlled Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2604 participants.

Also called NCT02173379

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 2,604 participants (enrolled count) (from the registry)
Sponsor
  • Abbott Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02173379
Other papers using this trial's data
  • 5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique Journal of the American College of Cardiology, 2023-07-18 DOI, PubMed 37207924

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Canada, Germany, Singapore (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02173379. Randomized; single masking; primary purpose treatment. Start 2014-07 (actual); primary completion 2022-04-06 (actual). Results posted on 2018-07-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Absorb IV Randomized Controlled Trial
Condition
Coronary Artery Stenosis
Condition
Coronary Disease
Condition
Coronary Stenosis
Intervention (Device)
Absorb BVS
Intervention (Device)
XIENCE
Lead sponsor
Abbott Medical Devices (class: industry)

Record details

Record id
cardio:ct-nct02173379
Content hash
8f678eff98d00474abb2fb0b00a9a6b7af4afc1cdf2c7a8f7204ced2bdbf4f82